CORTISONE ACETATE (cortisone acetate) by Molecular Devices is clinical pharmacology: naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. First approved in 2001.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
Cortisone acetate is an oral tablet containing a naturally occurring glucocorticoid used for replacement therapy in adrenocortical deficiency and as a potent anti-inflammatory agent across multiple organ systems. It works by modifying immune responses and producing profound metabolic effects throughout the body. This legacy corticosteroid remains a foundational therapy in endocrinology and rheumatology.
This mature product faces approaching loss of exclusivity with moderate competitive pressure (30), suggesting a shrinking commercial team focused on cost management and generic transition planning.
CLINICAL PHARMACOLOGY: Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
Working on cortisone acetate offers limited growth trajectory given its LOE-approaching status and zero linked job openings, but provides stability in a legacy product and exposure to generic transition strategy. Roles focus on cost optimization, market defense, and post-LOE planning rather than innovation and expansion.
Worked on CORTISONE ACETATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo